Clinical Trial Update: Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma

View source ↗

Summary

The document reports expanded access use of L-MTP-PE (mifamurtide) for osteosarcoma, providing patients outside of a formal trial with access to this treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Mifamurtide (L-MTP-PE) (mifamurtide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Osteosarcoma | Status: AVAILABLE